183 related articles for article (PubMed ID: 7663532)
21. Mephenytoin phenotyping: lack of haematologic effect and timing of urine collections.
Relling MV; Ayers D; Heideman RL
Pharmacogenetics; 1991 Oct; 1(1):42-9. PubMed ID: 1844822
[TBL] [Abstract][Full Text] [Related]
22. Mephenytoin as a probe for CYP2C19 phenotyping:effect of sample storage, intra-individual reproducibility and occurrence of adverse events.
Tamminga WJ; Wemer J; Oosterhuis B; Wieling J; Touw DJ; de Zeeuw RA; de Leij LF; Jonkman JH
Br J Clin Pharmacol; 2001 May; 51(5):471-4. PubMed ID: 11422005
[TBL] [Abstract][Full Text] [Related]
23. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin.
Ferguson RJ; De Morais SM; Benhamou S; Bouchardy C; Blaisdell J; Ibeanu G; Wilkinson GR; Sarich TC; Wright JM; Dayer P; Goldstein JA
J Pharmacol Exp Ther; 1998 Jan; 284(1):356-61. PubMed ID: 9435198
[TBL] [Abstract][Full Text] [Related]
24. Stereoselective 4'-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese.
Ieiri I; Mamiya K; Urae A; Wada Y; Kimura M; Irie S; Amamoto T; Kubota T; Yoshioka S; Nakamura K; Nakano S; Tashiro N; Higuchi S
Br J Clin Pharmacol; 1997 Apr; 43(4):441-5. PubMed ID: 9146858
[TBL] [Abstract][Full Text] [Related]
25. Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia.
Marandi T; Dahl ML; Rägo L; Kiivet R; Sjöqvist F
Eur J Clin Pharmacol; 1997; 53(3-4):257-60. PubMed ID: 9476041
[TBL] [Abstract][Full Text] [Related]
26. Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping Israeli ethnic groups.
Britzi M; Bialer M; Arcavi L; Shachbari A; Kapitulnik T; Soback S
Ther Drug Monit; 2000 Oct; 22(5):510-6. PubMed ID: 11034254
[TBL] [Abstract][Full Text] [Related]
27. Identification of human CYP2C19 residues that confer S-mephenytoin 4'-hydroxylation activity to CYP2C9.
Tsao CC; Wester MR; Ghanayem B; Coulter SJ; Chanas B; Johnson EF; Goldstein JA
Biochemistry; 2001 Feb; 40(7):1937-44. PubMed ID: 11329260
[TBL] [Abstract][Full Text] [Related]
28. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe.
Masimirembwa C; Bertilsson L; Johansson I; Hasler JA; Ingelman-Sundberg M
Clin Pharmacol Ther; 1995 Jun; 57(6):656-61. PubMed ID: 7781265
[TBL] [Abstract][Full Text] [Related]
29. Phenotype analysis of cytochrome P450 2C19 in Chinese subjects with mephenytoin S/R enantiomeric ratio in urine measured by chiral GC.
Yao TW; Zeng S; Wang TW; Chen SQ
Biomed Chromatogr; 2001 Feb; 15(1):9-13. PubMed ID: 11180294
[TBL] [Abstract][Full Text] [Related]
30. Genetic variations of S-mephenytoin 4'-hydroxylase (CYP2C19) in the Chinese population.
Xie HG
Life Sci; 2000 Feb; 66(14):PL175-81. PubMed ID: 10755474
[TBL] [Abstract][Full Text] [Related]
31. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.
Bertilsson L
Clin Pharmacokinet; 1995 Sep; 29(3):192-209. PubMed ID: 8521680
[TBL] [Abstract][Full Text] [Related]
32. Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin.
Ibeanu GC; Goldstein JA; Meyer U; Benhamou S; Bouchardy C; Dayer P; Ghanayem BI; Blaisdell J
J Pharmacol Exp Ther; 1998 Sep; 286(3):1490-5. PubMed ID: 9732415
[TBL] [Abstract][Full Text] [Related]
33. Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy.
Kimura M; Ieiri I; Wada Y; Mamiya K; Urae A; Iimori E; Sakai T; Otsubo K; Higuchi S
Br J Clin Pharmacol; 1999 Jan; 47(1):115-9. PubMed ID: 10073749
[TBL] [Abstract][Full Text] [Related]
34. CYP2C19 genotype does not represent a genetic predisposition in idiopathic systemic lupus erythematosus.
Kortunay S; Bozkurt A; Bathum L; Basci NE; Calgüneri M; Brøsen K; Kayaalp SO
Ann Rheum Dis; 1999 Mar; 58(3):182-5. PubMed ID: 10364917
[TBL] [Abstract][Full Text] [Related]
35. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin.
Ibeanu GC; Blaisdell J; Ferguson RJ; Ghanayem BI; Brosen K; Benhamou S; Bouchardy C; Wilkinson GR; Dayer P; Goldstein JA
J Pharmacol Exp Ther; 1999 Aug; 290(2):635-40. PubMed ID: 10411572
[TBL] [Abstract][Full Text] [Related]
36. [The molecular mechanism of polymorphism of S-mephenytoin hydroxylative metabolism].
Lou YQ; Kuang TY
Sheng Li Ke Xue Jin Zhan; 1995 Jan; 26(1):23-8. PubMed ID: 7604218
[TBL] [Abstract][Full Text] [Related]
37. Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent.
Xie HG; Kim RB; Stein CM; Wilkinson GR; Wood AJ
Br J Clin Pharmacol; 1999 Sep; 48(3):402-8. PubMed ID: 10510153
[TBL] [Abstract][Full Text] [Related]
38. Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.
Bathum L; Skjelbo E; Mutabingwa TK; Madsen H; Hørder M; Brøsen K
Br J Clin Pharmacol; 1999 Sep; 48(3):395-401. PubMed ID: 10510152
[TBL] [Abstract][Full Text] [Related]
39. P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism.
Hadama A; Ieiri I; Morita T; Kimura M; Urae A; Irie S; Kaneda T; Mamiya K; Tashiro N; Higuchi S; Otsubo K
Ther Drug Monit; 2001 Apr; 23(2):115-8. PubMed ID: 11294510
[TBL] [Abstract][Full Text] [Related]
40. Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients.
Koyama E; Tanaka T; Chiba K; Kawakatsu S; Morinobu S; Totsuka S; Ishizaki T
J Clin Psychopharmacol; 1996 Aug; 16(4):286-93. PubMed ID: 8835703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
